SNBL has invested in Trunk Solution Corporation (TSC) and it has become an SNBL Group subsidiary company as of July 31, 2018.
TSC is a company that focuses research on the best balanced posture. It markets science-supported health products including a patented wearable device to activate core muscles for those with neuromusculoskeletal conditions. TSC also offers services for physical therapy and corporate health programs.
This business partnership between SNBL and TSC will lead to improved health outcomes for many. This tie-up shows that SNBL Group is committed to freeing patients from suffering by supporting drug development and improving medical technology.
Attachments
Original document
Permalink
Disclaimer
Shin Nippon Biomedical Laboratories Ltd. published this content on 03 August 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 03 August 2018 07:55:01 UTC
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. is a Japan-based company mainly engaged in the provision of clinical trials and drug development services for pharmaceutical companies. The Company has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2013, the Company had 27 subsidiaries and one associated company.
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. 
